Revon Media
  • Newspaper
    • theHealth
    • @Halal
    • @green
    • @Pancing
    • myHealth
  • Live Edition
    • theHealth
    • @Halal
    • @green
    • @Pancing
    • myHealth
  • Media
    • theHealth
    • @Halal
    • @green
    • @Pancing
    • myHealth
  • About Us
  • Contact Us
No Result
View All Result
  • Newspaper
    • theHealth
    • @Halal
    • @green
    • @Pancing
    • myHealth
  • Live Edition
    • theHealth
    • @Halal
    • @green
    • @Pancing
    • myHealth
  • Media
    • theHealth
    • @Halal
    • @green
    • @Pancing
    • myHealth
  • About Us
  • Contact Us
No Result
View All Result
Revon Media
No Result
View All Result

Reducing the cost of treatment

Prevention is key
Share on FacebookShare on Twitter

Insulin is a critical drug that diabetic patients require continuous daily dosing.

The total insulin market is over RM200 million with about around four per cent compound annual growth rate (CAGR). Human insulin makes up about 56 per cent of that total, followed by insulin aspart and glargine.

Duopharma Biotech Berhad CEO (Commercial) Wan Amir-Jeffery Wan Abdul Majid shared: “The human insulin market in Malaysia is primarily a government market and is supplied mainly by two players, Duopharma Biotech/Biocon and Novo Nordisk.

“Duopharma is the exclusive marketing and distribution partner in the tripartite agreement signed with the MoH and Biocon, a manufacturer of insulins locally. After the expiry of the off-take agreement with the MoH in 2022, we have managed to secure a new contract for another three years to supply to the MoH until 2025.”

Wan Amir-Jeffery, CEO (Commercial), Duopharma Biotech Berhad

Regarding the high cost of insulin, Wan Amir-Jeffery explained: “Innovator medications in particular, are generally more costly than generic or biosimilar options.

“This is because innovator medications undergo rigorous research and development (R&D), clinical trials, marketing, education and knowledge sharing, etc., on the products. These cost a lot of money. The innovator brands will charge a premium price during the patent protection period, which is about 20 to 25 years.

“But, after the patent expires, other generic and biosimilar manufacturers, such as Duopharma Biotech and Biocon, can come into markets with their strengths and advantages.”

Biosimilars relate to a biopharmaceutical drug designed to have active properties similar to a previously licensed drug. Biosimilar drugs have established their bio-similarity and non-inferiority to the reference biologic drug.

Meanwhile, generic drugs contain identical medicinal ingredients to their reference products. They comprise small molecules that are chemically synthesised.

Generics and biosimilars help keep costs down to a certain degree. “They are more affordable than innovator brand insulins.

Prof Amrahi Buang, President, Malaysian Pharmacists Society

President of the Malaysian Pharmacists Society (MPS), Prof Amrahi Buang, shared his support for cost-effective and safe alternatives.

“Biosimilar alternatives allow more patients to use insulin in diabetes treatment. So, we should support biosimilars.”

He also emphasised the safety and efficacy of biosimilar insulins in the market.

According to Amrahi, the National Pharmaceutical Regulatory Agency (NPRA) safeguards the nation’s health by ensuring all medicinal products’ quality, safety and efficacy. Therefore, registered biosimilar insulins are guaranteed to be safe and effective.

– The Health

Tags: BiosimilarCover StoryDiabetesInsulinPublic healthThe Health 2023The Health Jan/Feb 2023theHealthTreatment cost
Previous Post

Prevention is key

Next Post

Sweet surrender

Live Edition Paper

NOV 2020 ePaper

OCT 2020 ePaper


 

Subscribe for free complimentary live editions:

Recent News

  • Exploring 5G strategies
    February 7, 2022
    The 5G TECH 2021 conference, themed “Digital Economy Recovery through 5G”, was […]
  • Sepsis with heart failure: A medical emergency
    December 21, 2022
    If a patient with sepsis develops heart failure and does not receive timely […]
  • Not ready for endemic phase yet
    November 29, 2021
    Dato’ Dr Suresh Kumar Senior Consultant, Infectious Disease Physician and Head […]
  • Fasting within the scope of halalan toyyiban
    April 28, 2022
    There are infinite rewards and better health BY AMAL A. M. ELGHARBAWY Islam […]
  • KPJ’s first smart hospital
    June 29, 2022
    KPJ Healthcare Berhad showcased its premier flagship hospital, Damansara […]

Connect

Office

Revon Media Sdn Bhd
A member of Revongen Corporation
Headquarters
Revongen Corporation Center,
Level 17, Top Glove Tower, No.16,
Persiaran Setia Dagang,Setia Alam,
Seksyen U13, 40170 Shah Alam,
Selangor Darul Ehsan, Malaysia.

Contact

Tel: +603 3359 1166
Fax: +6 03 3358 0303

Copyright © 2021 Revon Media Sdn Bhd. A publication of Revon Media Sdn Bhd. About Us | Contact Us | Privacy Policy | Terms of use

No Result
View All Result
  • Newspaper
    • theHealth
    • @Halal
    • @green
    • @Pancing
    • myHealth
  • Live Edition
    • theHealth
    • @Halal
    • @green
    • @Pancing
    • myHealth
  • Media
    • theHealth
    • @Halal
    • @green
    • @Pancing
    • myHealth
  • About Us
  • Contact Us

© 2021 Revon Media Sdn Bhd. A publication of Revon Media Sdn Bhd

Welcome Back!

Login to your account below

Forgotten Password?

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist